Redeye will return with an update following the recent successful fusion with IDL Biotech last week. With an acceptance rate translating to some 96% of the shares and votes in IDL Biotech, and the transaction soon to be fully completed, we now await further discussions with AroCell’s management in regard to its strategy going forward. Hence, we will re-assess the case and come back later during the summer with a more detailed take on AroCell and its fusion.